| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Pituitary Unit of the Department of
Neurosurgery*
and the Department of
Pathology,
IRCCS San Raffaele, University of
Milano, Milano, Italy
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
10 mm, whereas the frequency of corticotroph
macroadenomas is estimated to be 6 to 20% in large surgical
series,1-5
a value lower than that typical of other types
of secreting adenomas.6-7
Only a few studies have
investigated whether corticotroph macroadenomas differ in their
clinical and biochemical features from the more frequent
microadenomas.5,8 The reason for the low frequency of adrenocorticotropin (ACTH)-secreting macroadenomas has not yet been elucidated. It is likely that chronic glucocorticoid excess may play a role, as suggested by the development of aggressive tumors (Nelson’s syndrome) in about 20% of patients with Cushing’s disease treated by bilateral adrenalectomy.9 Theoretically, the rate of growth of pituitary tumors depends on the doubling time of the adenomatous cells. Cell doubling time is slowed by many factors, among which the most important are the death of some tumor cells by apoptosis (programmed cell death), ischemic, or hemorrhagic events, and the presence of a pool of quiescent cells that do not enter the mitotic cycle.10 Assessment of the growth fraction can be accomplished by determining the percentage of cells expressing the Ki-67 antigen, a nuclear protein of unknown function expressed only in cycling cells.11 Apoptosis is an active process requiring protein synthesis and specific endonucleolytic digestion of cellular DNA.12 The DNA fragmentation that ensues is one hallmark of apoptotic cell death.
Despite the interplay of both processes determines the type of neoplastic growth, only one study investigated the proliferation index of ACTH-secreting adenomas subdivided into micro- and macroadenomas,5 whereas the relationship between tumor size and apoptosis has never been addressed previously. Only one study13 reported the percentage of apoptotic cells in a heterogeneous group of pituitary adenomas, including 16 ACTH-secreting tumors. Therefore, we measured both the proliferation and apoptotic indices in a large series of ACTH-secreting adenomas subdivided according to tumor size.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
One hundred twelve patients operated on for Cushing’s disease
between January 1990 and June 1997 were eligible for the study.
Diagnosis of Cushing’s disease was based on standard clinical and
biochemical findings.1
Criteria of exclusion from the
study were previous pituitary surgery (11 patients), lack of pituitary
adenoma at histological analysis (26 patients), and tumor size <4 mm
(24 patients). The last exclusion criterion was selected because
measurement of both Ki-67 antigen and apoptosis in very small tumor
specimens may not be always reliable. Altogether, 51 patients, 43
female and 8 male, were included in the study. The mean age of the
patients was 34.6 ± 1.5 years (range, 12–61 years). The
estimated mean duration of disease was 4.6 ± 0.4 years. Maximum
tumor diameter was measured on preoperative magnetic resonance imaging
(MRI) or, in the smallest tumors, directly assessed by the surgeon at
operation. Patients were subdivided according to tumor size in two
groups: patients with microadenoma (maximum tumor diameter 10 mm;
group A, 36 patients) and patients with macroadenoma (maximum tumor
diameter >10 mm; group B, 15 patients). Eighteen patients (35%; 12 in
group A, 6 in group B) had received treatment with ketoconazole before
surgery; the drug was usually stopped at least 10 to 14 days before
operation. In all but three patients, free urinary cortisol level was
above the normal range immediately before surgery; their exclusion from
analyses that included previous treatment with ketoconazole did not
modify significantly any result. Successful outcome of surgery was
defined according to the following criteria: clinical remission of the
disease accompanied by postoperative hypocortisolism or, in the case of
normal serum and urinary cortisol levels, demonstration of normal
suppression of steroid levels during low-dose administration of
dexamethasone. If hypercortisolism recurred within 6 months after
surgery, patients were considered as treatment failures.1
Hormone Assays
Blood samples for hormone measurements were obtained in the morning after an overnight fast from hospitalized patients. The specimens for cortisol measurement were drawn into plastic tubes and allowed to clot at room temperature before being centrifuged at 2500 rpm for 10 minutes. The samples for ACTH measurement were collected into iced plastic tubes containing sodium EDTA plus Trasylol. The tubes were then centrifuged at 4°C for 10 minutes at 2500 rpm and the plasma was transferred into polypropylene tubes and stored at -20°C until assay.
Plasma ACTH was assayed in duplicate by a commercially available solid phase two-site immunoradiometric assay (CIS Diagnostici S.p.A., Tronzano Vercellese, Italy). Serum cortisol was assayed in duplicate by a commercially available immunoradiometric assay (Biorad S.p.A., Milano, Italy). Normal ranges for ACTH and cortisol were 10 to 80 ng/L and 50 to 250 µg/L, respectively.
Histological Analysis
Surgically removed specimens were fixed immediately in 10% buffered formalin and subsequently embedded in paraffin. Standard hematoxylin-eosin sections were used for diagnosis; standard immunocytochemistry using commercially available antisera was used to characterize neoplastic areas for the presence of prolactin (PRL; Immunotech S.A., Marseille, France), growth hormone (GH; Biomeda, Foster City, CA), ACTH (Signet, Dedham, MA), thyrotropin (Immunotech), luteinizing hormone (Immunotech), and follicle stimulating hormone (Immunotech). Analysis of MIB-1 immunostaining and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL; see below) was conducted in slides adjacent to those where immunocytochemistry was performed to avoid inclusion of normal peritumoral tissue.
MIB-1 Immunostaining
Proliferation activity of the tumor was determined by calculating
the percentage of cells expressing the Ki-67 antigen. To this aim we
used the monoclonal antibody MIB-1, which can be also used in
formalin-fixed material. MIB-1 immunostaining was performed using the
avidin-biotin-peroxidase complex method14
on 4-µm
sections mounted onto glass slides treated with poly-L-lysine and dried
until ready for use. Sections of human cecal appendix were used as
positive controls. Tissue sections were dewaxed and endogenous
peroxidase activity was blocked.15
Then, after antigen
retrieval by microwave treatment (two passages at 850 W of 5 minutes
each), sections were incubated with nonimmune rabbit serum at room
temperature for 20 minutes to block nonspecific links and then
incubated at 37°C for 60 minutes with MIB-1 monoclonal antibody
diluted 1:50 (Immunotech); no MIB-1 antibody was added on sections used
as negative controls. After rinsing, slides were incubated with rabbit
biotinylated anti-mouse IgG diluted 1:100 as secondary antibody for 30
minutes at room temperature and then exposed to
streptavidin-biotin-peroxidase complex (Vector Laboratories,
Burlingame, CA) for 30 minutes. After rinsing, sections were exposed in
the dark to the chromogen 3,3'-diaminobenzidine for 5 minutes, that
stains Ki-67 immunopositive nuclei with a dark brown color (Figure 1)
. Slides were lightly counterstained
with hematoxylin, dehydrated, cleared, and mounted. Because MIB-1
positive cells may be unevenly distributed in biopsy samples, the Ki-67
antigen labeling index (Ki-67 LI) was determined by counting a total of
at least 1000 neoplastic nuclei subdivided in 10 fields chosen randomly
at 400x magnification.
|
The method of TUNEL, originally described by Gavrieli and coworkers,16 was used after minor modifications. Briefly, tissue sections of 4 µm were mounted onto glass slides treated with poly-L-lysine, deparaffinized, hydrated, and treated for 10 minutes at 37°C with proteinase-K (Boehringer Mannheim, Mannheim, Germany; 20 µg/ml 10 mmol/L Tris-HCl buffer, pH 7.4). Slides were rinsed twice with PBS. Then, 50 µl of TUNEL reaction mixture (450 µl nucleotide mixture containing fluoresceinated dUTP in reaction buffer plus 50 µl enzyme TdT from calf thymus) were added to samples. To ensure homogeneous spread of TUNEL reaction mixture on tissue sections and to avoid evaporative loss, slides were covered with coverslips during incubation. Slides were incubated in a humidified chamber for 60 minutes at 37°C. After rinsing, slides were incubated with anti-fluorescein antibody, Fab fragment from sheep, conjugated to alkaline phosphatase for 30 minutes at room temperature (Boehringer Mannheim). Then, on each slide, 50 µl substrate solution (blue tetrazolium) were added and slides were incubated for 10 minutes at room temperature. Positive signal was defined as the presence of a distinct blue staining on nuclei of the neoplastic cells or on apoptotic bodies as morphologically defined. The apoptotic index was determined by counting a total of at least 1000 neoplastic nuclei subdivided in 10 fields chosen randomly at 400x magnification. Apoptotic cells were identified by TUNEL in conjunction with characteristic morphological changes, such as cell shrinkage, membrane blebbing, and chromatin condensation, to distinguish apoptotic cells and apoptotic bodies from necrotic cells, which were not considered as apoptotic cells. Sections of human cecal appendix were used as positive controls.
All Ki-67 LI and apoptotic index determinations were performed by a single pathologist (F. M.) who was unaware of the clinical characteristics of the patients.
Statistical Analysis
All data are expressed as the mean ± SE. Because ACTH, Ki-67
LI, and apoptotic index showed a markedly skewed distribution, they
were transformed logarithmically before statistical analysis; a value
of 0% was arbitrarily assigned to be 0.05%. However, in the text and
figures, ACTH, Ki-67 LI, and apoptosis index are given in the usual
decimal format. Student’s t-test for unpaired data was used
to compare continuous variables among groups. Correlation coefficients
between continuous variables were calculated by the method of least
squares. 
2
tabulation was used to compare
binomial proportions. Multivariate regression was performed to evaluate
the independent effect of the proliferation index on the success rate
of surgery. A P value of <0.05 was considered to indicate
statistical significance. All calculations were performed using the
statistical package StatView 4.0 (Abacus Concepts Inc., Berkeley, CA).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Thirty-six patients had a microadenoma (group A; mean tumor
diameter 5.9 ± 0.2 mm; range, 4–9 mm), whereas the remaining 15
patients had a macroadenoma (group B; mean tumor diameter 19.2 ±
1.2; range, 13–36 mm). No patient in group A had MRI evidence of sinus
cavernous involvement, whereas five patients in group B had involvement
of one cavernous sinus by the tumor. Two additional patients in group B
also showed tumor extension into the sphenoid sinus, whereas the
remaining eight patients had an intrasellar or suprasellar extending
macroadenoma. The clinical and hormonal characteristics of the two
groups are detailed in Table 1
. No
difference of age, sex distribution, or estimated duration of disease
was observed. Mean plasma ACTH level was significantly higher
(P < 0.01) in group B compared to group A
patients and showed a highly significant correlation with the maximum
tumor diameter (r = 0.67; P <
0.0001). Twelve patients in group A (33.3%) and 9 patients (60.0%) in
group B had basal ACTH above the normal range. The difference of mean
cortisol level was not significant, even though the P value
was very close to the significance level (P =
0.06). Overall, 45 patients, 41 with postoperative hypocortisolism and
4 with normal serum and urinary cortisol levels, were considered in
remission after operation. Outcome of surgery was significantly better
in group A (36 of 36 patients in remission; success rate 100%) than in
group B (10 out of 15 patients in remission; success rate 66.7%;
P < 0.01). The mean follow-up in this group of
patients was 26.5 ± 2.9 months, ranging from 2 to 71 months.
Recurrence of Cushing’s disease in this period occurred in three
patients, two in group A and one in group B, after 32, 55, and 71
months, respectively.
|
The mean Ki-67 LI in all patients was 4.7 ± 1.0%, ranging
from 0.1 to 40%. The highest value of 40% was recorded in a
34-year-old male patient with an invasive tumor measuring >30 mm in
maximum diameter. Although such a high value is often detected in
malignant tumors, our patient did not have evidence of any metastatic
lesion and experienced postoperative hypoadrenalism after apparent
total removal of the tumor. Ki-67 LI was not correlated with age at
operation, estimated duration of disease, female sex, previous
treatment with ketoconazole, plasma ACTH, or serum cortisol levels.
Group B patients had a significantly higher Ki-67 LI (9.3 ±
2.7%; range, 0.6–40.0%) than group A patients (2.8 ± 0.5%;
range, 0.1–9.0%; t = 3.38; P < 0.002; Figure 2
). Moreover, the Ki-67 LI was
significantly correlated with maximum tumor diameter in the whole study
group (r = 0.53; P < 0.01;
Figure 3
).
|
|
).
Moreover, maximum tumor diameter was only weakly correlated with the
apoptotic index (r = 0.28, P =
0.04). There was a significant correlation between Ki-67 LI and
apoptotic index in the whole group of patients
(r = 0.41, P < 0.01). Patients not in remission after surgery had a significantly higher Ki-67 LI than patients in remission (9.6 ± 2.6% vs. 4.2 ± 1.0, t = 2.15, P = 0.03), whereas the apoptotic index did not differ significantly (0.7 ± 0.3 vs. 1.1 ± 0.3%, t = -0.43, P = n.s.). However, stepwise regression analysis indicated that the apparent association between a high Ki-67 LI and a poor surgical outcome was not independent, since when all the other variables were considered together, only maximum tumor diameter and basal ACTH level remained significantly associated to a poor surgical outcome. Exclusion from the analysis of the four patients with postoperative eucortisolism rather than hypocortisolism did not modify the results.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Most patients with Cushing’s disease have very small tumors and
consequently the distinction between microadenomas and macroadenomas,
as well as the mechanism(s) underlying their different pattern of
growth, has not received much attention in the literature. The
frequency of ACTH-secreting macroadenomas (15 of 101, 15%), in our
population is similar to that reported in other large surgical
series,1,3,4
but lower than that of smaller
series.8,17
Although arbitrary, subdivision of pituitary
adenomas in micro- and macroadenomas has been widely accepted and, in
the case of PRL-secreting adenomas, the two groups seem to represent
entities differing in some biological characteristics.18
In the present study we found a significantly higher proliferation
index in ACTH-secreting macroadenomas compared to microadenomas. The
significant correlation between Ki-67 LI and maximum tumor diameter
further strengthens our finding. Moreover, it is also likely that the
magnitude of the difference would have been even greater had we not
excluded from the study patients with tumors smaller than 4 mm. Data on
the proliferation rate of ACTH-secreting adenomas are rather scanty. In
a retrospective study, Katznelson and coworkers5
reported
a higher Ki-67 LI in 16 corticotroph macroadenomas compared to 17
microadenomas, but the difference was only of borderline significance,
probably because it was influenced by the presence of a single elevated
value in the group of microadenomas (see Figure 3
of their paper). The
five patients described by Ikeda and coworkers17
had Ki-67
LI of 0.1, 1.7, 0.4, 0.1, and 0.2%, respectively, but they did not
report for comparison the Ki-67 LI in ACTH-secreting microadenomas
operated in the same period. Other studies found high Ki-67 LI values
in ACTH-secreting adenomas,19-21
but the number of
patients was small and the size of the tumor was not specified. The
relatively high frequency (about 30%) of ACTH-secreting tumors among
the few pituitary carcinomas reported to date in the
literature22,23
supports the conclusion that the
proliferative capacity of these adenomas is increased.
Which mechanism may cause the high proliferation index occurring in ACTH-secreting macroadenomas? High doses of glucocorticoids suppress the growth of the corticotrophic tumor cell line AtT2024 in vitro. Moreover, a positive correlation between the size of the corticotroph adenoma and the degree of insensitivity to glucocorticoid feedback was demonstrated in dogs in vivo.25 These data are consistent with studies in humans that showed a lack of cortisol suppression after administration of dexamethasone at high doses in patients with corticotroph macroadenomas only.5,8,17,26 It has been hypothesized that resistance to high doses of glucocorticoids may be caused by the occurrence of somatic mutation(s) affecting the glucocorticoid receptor or its expression.27,28 Adding our data to the above mentioned studies, we can speculate that, from the outset or during the course of the disease, a subset of ACTH-secreting microadenoma acquires a somatic mutation in the glucocorticoid receptor that renders the adenomatous cells insensitive to the high cortisol levels, thus unmasking the intrinsic high proliferative activity of these tumors. Further research in this area is needed to test the validity of such hypothesis.
Apoptosis was originally discovered as an important regulator of normal development and tissue homeostasis, but it has assumed increasing importance because of its perceived role in controlling the growth of neoplastic cells by counterbalancing their rate of proliferation.10,29,30 Theoretically, then, the high frequency of small tumors among patients with Cushing’s disease could also be explained by a high apoptotic index in microadenomas. Our data do not support this possibility. The apoptotic index was not different in the two groups of patients. On the contrary, corticotroph macroadenomas showed an insignificantly higher apoptotic index compared to microadenomas, and there was a weak but significant correlation between maximum tumor diameter and apoptotic index in the entire group of patients. Interestingly, we found a significant correlation between apoptosis and proliferative activity. The latter finding has also been reported in malignant neoplasms,31 particularly in brain tumors.32 It has been hypothesized that an increase of the proliferation activity within a cell population leads to exhaustion of factors that promote cell multiplication and inhibit apoptosis. Apoptosis in ACTH-secreting pituitary adenomas has been investigated rarely. In a recent report Kontogeorgos and coworkers using an in situ end labeling technique13 found a higher apoptotic index in functioning than in nonfunctioning adenomas. Corticotroph adenomas had apoptotic values lower than thyrotropic adenomas but similar to that of GH-, PRL-, and mixed GH/PRL-secreting adenomas.13 At variance with our finding, the apoptotic index was higher in 5 ACTH-secreting microadenomas than in the remaining 10 macroadenomas; however, the difference was not significant.13
Outcome of surgery was not influenced by either proliferation or apoptotic index when a multivariate analysis was performed. Tumor size was the strongest predictor of surgical outcome and eliminated the apparent significant association found in the univariate analysis between Ki-67 LI and surgical outcome. Our data do not support the use in routine clinical practice of proliferation and apoptotic indices in patients with Cushing’s disease. However, because of the small number of patients with recurrent Cushing’s disease and the relatively short follow-up, we cannot evaluate their importance in predicting the long term prognosis of surgically treated Cushing’s disease.
We found a significant linear correlation between maximum tumor diameter and baseline plasma ACTH level, thus reinforcing the finding reported by Selvais and coworkers8 of a similar correlation between the tumor volume and mean plasma ACTH value. In another case control study5 the percentage of macroadenoma patients with ACTH level above the appropriate normal range (78%) was higher than in microadenoma patients (46%; P = 0.05 by Fisher’s exact test). The relationship between tumor size and peripheral level of the secreted hormone is typical of the other types of secreting pituitary adenomas, such as prolactinomas33 and acromegaly.34 Basal cortisol levels were higher in macroadenoma patients, but the difference did not reach the significance level. A similar trend was observed in other reports that assessed the urinary free cortisol or 17-OHCS levels.5,8
In conclusion, our study demonstrates that ACTH-secreting macroadenomas have a significantly higher proliferation index than microadenomas, whereas the apoptotic index is similar in the two groups. It seems reasonable to hypothesize that the difference of the proliferation activity is the principal characteristic underlying the different pattern of growth among ACTH-secreting tumors. Further studies are needed to clarify the mechanism(s) causing the growth advantage of ACTH-secreting macroadenoma.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported in part by grants from the Ministero della Universit
e della Ricerca Scientifica e Tecnologica (MURST), Rome.
Accepted for publication September 4, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts. Acta Neuropathol 1992, 84:178-183[Medline]
This article has been cited by other articles:
 |
|
 |
|
  Y. S. Woo, A. M. Isidori, W. Z. Wat, G. A. Kaltsas, F. Afshar, I. Sabin, P. J. Jenkins, J. P. Monson, G. M. Besser, and A. B. Grossman Clinical and Biochemical Characteristics of Adrenocorticotropin-Secreting Macroadenomas J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4963 - 4969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Losa, A Vimercati, S Acerno, R L Barzaghi, P Mortini, F Mangili, M R Terreni, G Santambrogio, and M Giovanelli Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma J. Neurol. Neurosurg. Psychiatry, June 1, 2004; 75(6): 889 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Pereira, M. O. van Aken, H. van Dulken, P. J. Schutte, N. R. Biermasz, J. W. A. Smit, F. Roelfsema, and J. A. Romijn Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushing's Disease J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5858 - 5864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Losa, P. Mortini, R. Barzaghi, L. Gioia, and M. Giovanelli Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3180 - 3186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Losa, E. Ciccarelli, P. Mortini, R. Barzaghi, D. Gaia, G. Faccani, M. Papotti, F. Mangili, M. R. Terreni, F. Camanni, et al. Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5194 - 5200. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
